Legend Biotech’s In Vivo CAR-T Therapy LB2501 Achieves Full Remissions in Initial Lymphoma Trial, Signaling a Potential Paradigm Shift in Cell Therapy
Shanghai, China – June 3, 2026 – Legend Biotech, a prominent biopharmaceutical company, has announced...
